TY - JOUR
T1 - Diet/exercise Versus pioglitazone
T2 - Effects of insulin sensitization with decreasing or increasing fat mass on adipokines and inflammatory markers
AU - Shadid, Samyah
AU - Stehouwer, Coen D.A.
AU - Jensen, Michael D.
N1 - Funding Information:
This work was supported by Grants DK40484, DK50456, and RR00585 from the U.S. Public Health Service, the Mayo Foundation, and Takeda Pharmaceuticals. S.S. was partly sponsored by Novo/Nordisk.
PY - 2006
Y1 - 2006
N2 - Background: Plasma adipokine concentrations are variably related to fatness/insulin resistance and may act via endocrine mechanisms. We assessed the relationship among plasma adipokine concentrations and their relationship with insulin sensitivity and body composition in obese adults before and after insulin sensitization accomplished using diet/exercise or pioglitazone. Methods: Plasma adipokine concentrations, insulin sensitivity, and body composition were assessed in 39 upper-body obese insulin-resistant, nondiabetic adults before and after 19 wk of diet/exercise or 30 mg/d pioglitazone. Results: Diet/exercise reduced body fat and visceral fat and improved insulin sensitivity parameters; pioglitazone improved insulin sensitivity to a similar degree but increased body fat. Adiponectin increased more after pioglitazone (4770 ± 487 vs. 8351 ± 693.6 ng/ml, P < 0.001) than after diet/exercise (4704 ± 367 to 5426 ± 325.3 ng/ml, P < 0.01), whereas TNFα, IL-6, and resistin did not change. C-reactive protein decreased with diet/exercise. Adipokine concentrations were not correlated with each other at baseline or after insulin sensitization, except TNFα and IL-6 (r = 0.43, P < 0.05); IL-6 was inversely correlated with resistin. Only adiponectin was correlated (P < 0.05) with indices of insulin sensitivity. Adiponectin concentrations were inversely correlated with visceral fat and with sc fat depots in men but positively correlated with sc fat in women. Conclusion: Plasma adipokine concentrations were not consistently interrelated, and only adiponectin displayed the expected relationship with insulin sensitivity and sensitization. These findings do not support an endocrine role for resistin, TNFα, and IL-6 in mediating changes in insulin resistance after diet/exercise or pioglitazone.
AB - Background: Plasma adipokine concentrations are variably related to fatness/insulin resistance and may act via endocrine mechanisms. We assessed the relationship among plasma adipokine concentrations and their relationship with insulin sensitivity and body composition in obese adults before and after insulin sensitization accomplished using diet/exercise or pioglitazone. Methods: Plasma adipokine concentrations, insulin sensitivity, and body composition were assessed in 39 upper-body obese insulin-resistant, nondiabetic adults before and after 19 wk of diet/exercise or 30 mg/d pioglitazone. Results: Diet/exercise reduced body fat and visceral fat and improved insulin sensitivity parameters; pioglitazone improved insulin sensitivity to a similar degree but increased body fat. Adiponectin increased more after pioglitazone (4770 ± 487 vs. 8351 ± 693.6 ng/ml, P < 0.001) than after diet/exercise (4704 ± 367 to 5426 ± 325.3 ng/ml, P < 0.01), whereas TNFα, IL-6, and resistin did not change. C-reactive protein decreased with diet/exercise. Adipokine concentrations were not correlated with each other at baseline or after insulin sensitization, except TNFα and IL-6 (r = 0.43, P < 0.05); IL-6 was inversely correlated with resistin. Only adiponectin was correlated (P < 0.05) with indices of insulin sensitivity. Adiponectin concentrations were inversely correlated with visceral fat and with sc fat depots in men but positively correlated with sc fat in women. Conclusion: Plasma adipokine concentrations were not consistently interrelated, and only adiponectin displayed the expected relationship with insulin sensitivity and sensitization. These findings do not support an endocrine role for resistin, TNFα, and IL-6 in mediating changes in insulin resistance after diet/exercise or pioglitazone.
UR - http://www.scopus.com/inward/record.url?scp=33748755548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748755548&partnerID=8YFLogxK
U2 - 10.1210/jc.2006-0015
DO - 10.1210/jc.2006-0015
M3 - Article
C2 - 16804048
AN - SCOPUS:33748755548
SN - 0021-972X
VL - 91
SP - 3418
EP - 3425
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 9
ER -